ACHV stock icon

Achieve Life Sciences
ACHV

$4.9
3.73%
 

About: Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

Employees: 22

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

802% more call options, than puts

Call options by funds: $935K | Put options by funds: $104K

478% more capital invested

Capital invested by funds: $11.2M [Q4 2023] → $64.9M (+$53.7M) [Q1 2024]

157% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 7

37% more funds holding

Funds holding: 30 [Q4 2023] → 41 (+11) [Q1 2024]

35.18% more ownership

Funds ownership: 12.88% [Q4 2023] → 48.06% (+35.18%) [Q1 2024]

33% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 9

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$11
124%
upside
Avg. target
$15
206%
upside
High target
$20
308%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Oppenheimer
Francois Brisebois
124%upside
$11
Outperform
Maintained
13 May 2024
JonesTrading
Justin Walsh
308%upside
$20
Buy
Initiated
17 Apr 2024
Oppenheimer
Francois Brisebois
267%upside
$18
Outperform
Reiterated
1 Apr 2024
Lake Street
Thomas Flaten
124%upside
$11
Buy
Maintained
5 Mar 2024

Financial journalist opinion